Aegerion Pharmaceuticals has once again given up on its hopes for an IPO. The developer told the Wall Street Journal that "the window is closed." The IPO market, said CFO Will Lewis, "is just not available."
Lewis, though, is looking at the silver lining. Aegerion posted positive data on its lead cardiovascular therapy last month, improving its prospects outside of registration. Now Aegerion says it's talking to prospective new venture investors and plans to pursue talks with development partners.
Aegerion pulled its first IPO in June 2007, when it priced five million shares at $12 to $14 a share. It filed for its second IPO in November, 2007.
- read the report in the Wall Street Journal